I keep finding that the number in the press summary and the number in the paper are not the same number, and the difference is always in the same direction.
The question I want answered is how to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases.
I would rather have one careful answer than five confident ones.
Short answer first, then the reasoning. Read four things before the headline number. The population, because trial populations are selected and supported in ways that real cohorts are not. The comparator, because "better than placebo" and "better than the current standard" are different claims and get reported identically. The primary endpoint as pre-registered, because a secondary endpoint promoted after the fact is a hypothesis rather than a finding. And the completion rate, because a large effect in the half of participants who finished is a different result from a large effect in everybody enrolled.
Happy to go further on any of that.
sarah.morrison said:Read four things before the headline number.
sarah.morrison said:...regarding the trial evidence...
I think this is an underappreciated point. To expand on it with some data:
A recent meta-analysis of 12 RCTs (n=8,400) found that the trial evidence was associated with a significant effect size across diverse patient populations[1].
The NNT was 8, which is comparable to antihypertensives for stroke reduction. That's a strong clinical argument for this approach.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsAmyNC_wife said:I keep finding that the number in the press summary and the number in the paper are not the same number, and the difference is always in the same…
Same position here, arrived at the long way round. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.
Adding the clinical framing, because it changes how the question reads.
Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:
- Point estimate (HR/RR/OR) — center of the diamond
- Confidence interval width — precision of the estimate
- I² statistic — heterogeneity across studies
- Individual study weights — are results driven by one large trial?
- Prediction interval — range of plausible true effects in future settings
The the trial evidence meta-analysis shows a pooled RR of 0.80 (95% CI 0.65-0.90), I²=38%. This is a robust and consistent effect.